14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IRMD vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRMD carries a Unified Composite Score of 40.3/100 (SELL) at $84.42 (35.0x Forward P/E, 32.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).
Growth vs. Quality Trade-Off: IRMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. DCTH 35.9/100 SELL) and 0.73β · 55% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although IRMD compares more favorably head-to-head, both IRMD (40.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: IRMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment82.4% of Rev ($91M)
90D Engineering Disclosures0 Published
Investor FAQ IRMD vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRMD carries a Unified Composite Score of 40.3/100 (SELL) at $84.42 (35.0x Forward P/E, 32.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Growth vs. Quality Trade-Off: IRMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. DCTH 35.9/100 SELL) and 0.73β · 55% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although IRMD compares more favorably head-to-head, both IRMD (40.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IRMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: IRMD posts +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IRMD cumulative revenue shifted +166.7% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, IRMD deploys 43.2% of Rev ($39M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
IRMD screens cheaper on headline valuation multiples. IRMD trades at 35.0x Forward P/E, 45.3x Trailing P/E, 4.46x PEG, and 12.1x EV/Revenue (28.7% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRMD (23.4% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IRMD carries 34.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.73β · 55% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.